STOCK TITAN
  1. Home
  2. Sec-filings
  3. INKT
  4. [8-K] MiNK Therapeutics, Inc. Reports Material Event

MiNK Therapeutics (INKT) narrows Q2 2026 loss, reports early Phase 2 lung data

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. reported second quarter 2026 results and clinical progress for its lead iNKT cell therapy, agenT-797. Cash and cash equivalents were $8.8 million as of June 30, 2026. Net loss for the quarter was $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, in the second quarter of 2025. For the first six months of 2026, net loss was $5.9 million, or $1.20 per share, versus $7.0 million, or $1.76 per share, a decrease attributed to expense discipline.

Clinically, MiNK reported initial Day 28 observations from its randomized Phase 2 trial C-1300-02 of agenT-797 in acute lung injury/ARDS, with treated patients alive at Day 28, improved oxygenation, infection control, and no major serious adverse events attributed to agenT-797 in these initial patients. The company also launched a paid, per-patient, physician-initiated named-patient access program for agenT-797 in Brazil, which may generate non-promotional revenue while expanding access under regulatory oversight.

Positive

  • Net loss decreased from $4.2 million in Q2 2025 to $3.1 million in Q2 2026, with six‑month net loss improving from $7.0 million to $5.9 million, reflecting expense discipline.

Negative

  • None.

Filing Explained

Brazil access may generate product revenue, but each patient still requires authorization and agenT-797 lacks marketing approval.

The August 13, 2026 Form 8-K furnishes second-quarter results and states that MiNK Therapeutics established a paid Brazil named-patient program; access remains case-by-case, not a commercial launch or marketing authorization.

The filing defines named-patient access as a treating physician’s request for an unregistered medicine for one identified patient, with each request subject to Brazilian regulatory authorization; the program may generate product revenue but does not establish approval or safety and efficacy.

Although the release reports that initial treated patients were alive at Day 28 with other favorable observations, it states that these observations come from a small number of patients, are preliminary, and are not controlled comparisons.

Enrollment continues in Ukraine, U.S. site activation is underway, and the filing says additional trial data are expected in early 2027.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Cash and cash equivalents $8.8 million As of June 30, 2026
Net loss Q2 2026 $3.1 million Quarter ended June 30, 2026
Net loss per share Q2 2026 $0.62 per share Quarter ended June 30, 2026
Net loss Q2 2025 $4.2 million Quarter ended June 30, 2025
Net loss six months 2026 $5.9 million Six months ended June 30, 2026
Net loss six months 2025 $7.0 million Six months ended June 30, 2025
Cash and cash equivalents Dec 31, 2025 $13.4 million As of December 31, 2025
named-patient access regulatory
"First paid international named-patient access program established for physicians"
Named-patient access is a regulatory pathway that allows a doctor to obtain an unapproved medicine or medical product for a specific individual patient who has no satisfactory treatment options. Think of it like a special-order request for a single person before a product is officially approved for general sale; it typically requires physician justification and some form of regulatory or manufacturer approval. For investors, named-patient access can signal early clinical demand, regulatory interactions, and limited near-term revenue or safety data outside formal trials.
bronchoalveolar lavage medical
"Serum and bronchoalveolar lavage analyses showed reduced inflammatory markers"
A bronchoalveolar lavage is a medical procedure that rinses a small area of the lung with fluid and then collects that fluid for analysis, like flushing and examining the inside of a pipe to see what’s inside. Investors care because results can reveal infection, inflammation, or drug-related lung effects that influence clinical trial outcomes, regulatory decisions and market perception of respiratory therapies or safety profile of systemic drugs.
allogeneic iNKT cell therapies medical
"developing off-the-shelf allogeneic iNKT cell therapies for life-threatening conditions"
lymphodepletion medical
"requires no apheresis, patient-specific manufacturing, HLA matching, or lymphodepletion"
Lymphodepletion is a short medical treatment that lowers a patient’s lymphocytes, the immune cells that can interfere with certain cell-based therapies, to create a more supportive environment for the new therapy to work. Think of it like clearing a crowded garden bed before planting seeds: by temporarily reducing competing cells, the engineered therapy can take hold more effectively. Investors watch lymphodepletion because it affects clinical trial results, safety profiles, treatment adoption, and overall commercial potential.
acute respiratory distress syndrome medical
"acute lung injury and ARDS remain among the most serious unresolved conditions"
Acute respiratory distress syndrome (ARDS) is a sudden, severe lung condition in which the air sacs fill with fluid or collapse, making it hard for oxygen to pass into the bloodstream — imagine a sponge that can’t hold air. It matters to investors because ARDS drives demand for critical care treatments, ventilators, drugs and longer hospital stays, influences clinical trial design and approval chances for therapies, and can materially affect healthcare costs and company revenues tied to respiratory care.
Net loss $3.1 million vs $4.2 million in Q2 2025
Net loss per share $0.62 vs $1.06 in Q2 2025
Six-month net loss $5.9 million vs $7.0 million for six months ended June 30, 2025
Cash and cash equivalents $8.8 million vs $13.4 million as of December 31, 2025

FAQ

What were MiNK Therapeutics (INKT) cash levels at June 30, 2026?
MiNK Therapeutics reported $8.8 million in cash and cash equivalents as of June 30, 2026. This compares with $9.5 million as of March 31, 2026, and $13.4 million as of December 31, 2025, indicating ongoing cash use.

How did MiNK Therapeutics (INKT) net loss change in Q2 2026?
Net loss for Q2 2026 was $3.1 million, or $0.62 per share. This compares with a net loss of $4.2 million, or $1.06 per share, in Q2 2025, showing a lower loss year over year.

What were MiNK Therapeutics (INKT) results for the first six months of 2026?
For the six months ended June 30, 2026, MiNK reported a net loss of $5.9 million, or $1.20 per share. This compares with a net loss of $7.0 million, or $1.76 per share, for the same period in 2025, reflecting lower expenses.

What clinical progress did MiNK Therapeutics (INKT) report for agenT-797?
MiNK reported initial Day 28 observations from its randomized Phase 2 trial C-1300-02 in acute lung injury/ARDS. Initial agenT-797–treated patients were alive and afebrile at Day 28 with improved oxygenation, infection control, and no major serious adverse events attributed to agenT-797.

What is MiNK Therapeutics (INKT) named-patient access program in Brazil?
MiNK established a paid international named-patient access program in Brazil for agenT-797. Physicians can request the unapproved therapy for individual patients, subject to Brazilian regulatory authorization, generating per‑patient revenue while not constituting a commercial launch.

How is MiNK Therapeutics (INKT) expanding its Phase 2 lung injury trial?
The randomized Phase 2 trial C-1300-02 began dosing in Lviv, Ukraine, and is under an active U.S. IND. Enrollment continues in Lviv, with U.S. clinical center activation underway and additional data expected in early 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001840229false00018402292026-08-132026-08-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2026

 

 

MiNK Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40908

82-2142067

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

149 Fifth Avenue

Suite 500

 

New York, New York

 

10010

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 212 994-8250

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.00001 per share

 

INKT

 

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2026, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished herewith:

99.1 Press Release dated August 13, 2026

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

Date:

August 13, 2026

By:

/s/ Jennifer S. Buell

 

 

 

Jennifer S. Buell, President and Chief Executive Officer

 

 

 

 

 

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

 

•
First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, infection control, and liberation from ventilator and vasopressor support
•
Serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery and tissue repair; no major serious adverse events were attributed to agenT-797
•
First paid international named-patient access program established for physicians to request access to agenT-797, subject to per-patient regulatory authorization; building cross-border infrastructure and access to an off-the-shelf cell therapy

 

NEW YORK, NY — August 13, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune disorders, today reported financial results for the second quarter ended June 30, 2026, and provided an update on the clinical advancement of its lead candidate, agenT-797.

The second quarter marked MiNK's transition from single-arm clinical experience to randomized clinical validation. The Company dosed its first patient in C-1300-02 within days of Ministry of Health authorization in Ukraine, and has since reported Day 28 observations in ventilated, critically ill patients treated in an active conflict environment — a pace made possible by a therapy that ships from inventory and requires no apheresis, patient-specific manufacturing, HLA matching, or lymphodepletion.

“This quarter reflects the transition of our iNKT platform from scientific thesis to clinical execution,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. “Severe lung injury remains one of the largest unresolved problems in medicine, with no approved therapy shown to reduce mortality. Our randomized study in acute lung injury and ARDS gives us an opportunity to test that thesis prospectively while also demonstrating an important practical advantage of agenT-797. It is an off-the-shelf therapy that can be rapidly deployed without patient-specific manufacturing, HLA-matching or lymphodepletion. As our programs advance, we are building a body of clinical evidence around the potential of iNKT cells to restore immune function across therapeutic areas.”

Second Quarter 2026 and Recent Highlights

Randomized Phase 2 Trial in Acute Lung Injury and ARDS

•
Targets a high-mortality unmet need in critical care. Acute lung injury and ARDS remain among the most serious unresolved conditions in critical care, with mortality exceeding 40-50% and no approved therapies shown to reduce mortality.i Critically ill patients often deteriorate because severe lung injury can trigger broader immune dysfunction, including impaired pathogen control, infection susceptibility, and organ dysfunction.
•
Randomized Phase 2 dosing initiated in May 2026. MiNK began dosing at First Lviv Territorial Medical Union in Lviv, Ukraine, in collaboration with UNBROKEN Ukraine, within days of receiving Ministry of Health authorization. C-1300-02 (NCT07615010) is evaluating agenT-797 plus standard of care versus placebo plus standard of care in adults with acute lung injury and moderate-to-severe hypoxemic respiratory failure meeting Global ARDS Definition criteria. The study is being conducted under an active U.S. IND.
•
Initial Day 28 observations presented at the Military Health System Research Symposium (MHSRS). Dr. Terese C. Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK, presented initial observations with co-authors from First Lviv Territorial Medical Union. The initial agenT-797–treated patients were alive and afebrile at Day 28, with improved oxygenation and liberation from ventilator and vasopressor support. Microbiologic findings indicated control of baseline infections. Serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery, epithelial repair and pulmonary vascular recovery. No major serious adverse events were attributed to agenT-797 in these initial patients.

 

 

 

 

•
U.S. expansion in progress. Enrollment continues in Lviv, and activation of U.S. clinical centers is underway. Additional data are expected in early 2027.

Paid International Named-Patient Access

•
First paid international access program established. MiNK is collaborating with Orphan Drug Consulting (ODC) to support physician-initiated requests for agenT-797 for individually identified patients. The program expands access for patients with serious unmet medical need and provides MiNK with program revenue for product supplied. Each request is initiated by the treating physician and remains subject to case-by-case Brazilian regulatory authorization. The program is not a commercial launch or marketing authorization.
•
Access, revenue and scalable international infrastructure. ODC supports local regulatory submissions, importation, cold-chain logistics and pharmacovigilance. Product will be supplied on a paid, per-patient basis in accordance with applicable Brazilian access regulations. The program may result in non-promotional income to MiNK while establishing the operational infrastructure needed to support responsible access to agenT-797 in additional international markets.

Translational and Scientific Progress

•
ATS 2026 and peer-reviewed publication (May 2026). Data presented at the American Thoracic Society International Conference and published concurrently in Clinical Immunology Communications showed pathogen suppression, lung immune restoration and activation of tissue-repair pathways following administration of agenT-797 and N-803 (Anktiva®), an FDA-approved IL-15 superagonist, in Coccidioides infection.
•
ASGCT 2026 (May 2026). MiNK presented clinical evidence that a single off-the-shelf iNKT-cell product manufactured from the same donor batch produced context-dependent immune activity—immune activation in cancer and anti-inflammatory activity in ARDS—without genetic engineering.

Financial Results

Cash and cash equivalents were $8.8 million as of June 30, 2026, compared with $9.5 million as of March 31, 2026, and $13.4 million as of December 31, 2025. Net loss for the second quarter of 2026 was $3.1 million, or $0.62 per share, compared with $4.2 million, or $1.06 per share, for the second quarter of 2025. For the six months ended June 30, 2026, net loss was $5.9 million, or $1.20 per share, compared with $7.0 million, or $1.76 per share, for the same period in 2025. The year-over-year improvement reflects continued expense discipline.

img1737559_0.gif

Second Quarter 2026 Financial Results Conference Call and Webcast

 

 

 

 

MiNK will host a conference call and webcast today at 8:30 a.m. ET to discuss its financial results, provide clinical updates on agenT-797 in lung injury and highlight important business updates.

 

Conference Participant Dial Information

United States - New York

(646) 307-1963

USA & Canada - Toll-Free

(800) 715-9871

Conference ID -

8767945

 

Webcast & Replay Information
Live event link: https://edge.media-server.com/mmc/p/zkuebhpc
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations

About Mink Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic iNKT cell therapies for life-threatening conditions driven by immune dysfunction. The company's lead program, agenT-797, is being evaluated in acute lung injury and critical illness, with a pipeline that extends across immuno-oncology, transplant medicine, and other settings where dysregulated immunity is a driver of morbidity and mortality. MiNK believes that iNKT cell biology, because of its regulatory role across innate and adaptive immunity, may represent a foundational approach to immune restoration applicable across a broad range of conditions. For more information, visit www.minktherapeutics.com.

About the Named-Patient Access Program in Brazil

Named-patient access refers to a physician-initiated request for an unregistered medicine for an individually identified patient, subject to authorization by the competent health authority. MiNK's program launched in Brazil and is administered in collaboration with Orphan Drug Consulting (ODC), which acts as MiNK's local partner for per-patient regulatory submissions, importation, cold-chain handling, and adverse event reporting. Access under the program is initiated only by a treating physician, who is responsible for determining whether use is medically appropriate for a particular patient, for obtaining informed consent, and for the clinical management and monitoring of that patient. MiNK does not identify, recruit, solicit, or select patients, does not compensate physicians for requesting the product, and does not conduct promotional activity with respect to agenT-797 in Brazil or in any other jurisdiction. agenT-797 has not been approved for marketing by the Brazilian Health Regulatory Agency (ANVISA), the U.S. Food and Drug Administration, or any other regulatory authority, and its safety and efficacy have not been established. Availability under the program does not imply that agenT-797 is safe or effective for any use, and the program is not a commercial launch. The program is separate from, and is not a substitute for, participation in MiNK's clinical trials; patients who may be eligible for C-1300-02 or another MiNK-sponsored study will be directed to those studies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the therapeutic potential, safety, clinical benefit, and development plans for agenT-797 and MiNK's other iNKT-based programs; the design, enrollment, site activation, and timing of data from the C-1300-02 trial; the establishment, scope, operation, regulatory basis, and continuation of the Company's named-patient access program in Brazil, including whether per-patient authorizations will be granted and whether the program will generate any receipts; the sufficiency of the Company's cash resources and expected operating runway; and anticipated milestones. Initial observations from a small number of patients in an ongoing, blinded randomized trial are preliminary, are not controlled comparisons, and may not be predictive of results in additional patients or of the trial's ultimate outcome. Observations from patients treated outside of a controlled clinical trial, including under a named-patient program, are uncontrolled and are not evidence of safety or efficacy. Actual results may differ materially from those expressed or implied. These statements involve

 

 

 

 

risks and uncertainties, including those described under “Risk Factors” in MiNK's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. MiNK undertakes no obligation to update these statements except as required by law.

 

References

i Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315(8):788–800.

Contacts

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
 

Source: MiNK Therapeutics

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents